Term
|
Definition
| i.v. administration b/c catecholamine highly metabolized; low amt to CNS |
|
|
Term
|
Definition
| affects dose dependent; i.v. administration b/c catecholamine highly metabolized; low amt to CNS |
|
|
Term
|
Definition
| i.v. administration b/c catecholamine highly metabolized; low amt to CNS |
|
|
Term
|
Definition
| affects dose dependent; i.v. administration b/c catecholamine highly metabolized; gets to CNS |
|
|
Term
|
Definition
| i.v. administration b/c catecholamine highly metabolized |
|
|
Term
|
Definition
| oral admin; in CNS produrg metabolized to methyldopamine and methylnorepinephrine |
|
|
Term
|
Definition
| i.v. administrations even though non-catecholamine agonist |
|
|
Term
|
Definition
| i.v. administration initially, oral thereafter |
|
|
Term
|
Definition
| even though inhaled, my have systemic affect of HR increase |
|
|
Term
|
Definition
| even though inhaled, my have systemic affect of HR increase |
|
|
Term
|
Definition
| some tricyclic anti-depressants do this too |
|
|
Term
|
Definition
| important drug interaction-high levels in certain cheeses, fermented sausages, wines, and beer; if on an MAO inhibitor may have HTN crisis |
|
|
Term
|
Definition
| potent CNS stimulant; methamphetamine even more potent |
|
|
Term
|
Definition
| has wide spread adrenergic affects so now use more selective ß2 agonist |
|
|
Term
|
Definition
| not for asthmatics; OTC - pseudophed |
|
|
Term
|
Definition
| not cross BBB; SE - diarrhea, orthostatic hypotension, sexual dysfunction; drug interactions with cocaine and tricyclic antidepressants b/c block UPTAKE 1 |
|
|
Term
|
Definition
| old Chinese herbal remedy; does cross BBB so major SE - depression and suicidal tendencies b/c interferes with serotonin; also causes diarrhea |
|
|
Term
|
Definition
| SE - tachycardia, salt/water retention, orthostatic hypotension |
|
|
Term
|
Definition
| SE - tachycardia, salt/water retention, orthostatic hypotension |
|
|
Term
|
Definition
| decreases vascular tone of both arterioles and veins, decreasing both pre- and after-load; no increase in HR or CO b/c a2 not affected so less NE released to act on ß1 |
|
|
Term
|
Definition
| 4-hydroxypropranolol less active metabolite; SE - bradycardia, hypotension, bronchospasm (not for asthmatics), hypoglycemia (not for DM), low CO (not for CHF) |
|
|
Term
|
Definition
| small amount absorbed systemically so use with caution in heart dz pt |
|
|
Term
|
Definition
| SE - less bronchoconstriction (still not recommended for asthmatics |
|
|
Term
|
Definition
| quickly metabolized by plasma esterases in RBCs |
|
|
Term
|
Definition
| don't use if obstructed; never i.v. b/c NO release and massive vasodilation; contraindications - asthma, CHF, peptic ulcer |
|
|
Term
|
Definition
| never i.v. b/c NO release and massive vasodilation; contraindications - asthma, CHF, peptic ulcer |
|
|
Term
|
Definition
| toxicity - remove source of poisoning, maintain patent airway, atropine primary anecdote, pralidoxime anecdote |
|
|
Term
|
Definition
| toxicity - remove source of poisoning, maintain patent airway, atropine primary anecdote, pralidoxime anecdote |
|
|
Term
|
Definition
| toxicity - remove source of poisoning, maintain patent airway, atropine primary anecdote, pralidoxime anecdote |
|
|
Term
|
Definition
| does not cross BBB, needs to be administered quickly b/c enzyme is quickly unfolded and degraded |
|
|
Term
|
Definition
| SE - no sweating or salivation, cutaneous vasodilation, mydriasis, CNS affects; contraindications - glaucoma, prostatic hypertrophy, tachycardia |
|
|
Term
|
Definition
| SE - no sweating or salivation, cutaneous vasodilation, mydriasis, CNS affects; contraindications - glaucoma, prostatic hypertrophy, tachycardia |
|
|
Term
|
Definition
| SE - no sweating or salivation, cutaneous vasodilation, mydriasis, CNS affects; contraindications - glaucoma, prostatic hypertrophy, tachycardia |
|
|
Term
|
Definition
| blocks predominant tone (SNS or PNS) |
|
|
Term
|
Definition
| short duration of action b/c metabolized by pseudocholinesterases in serum, not acetylcholinesterase; slight decrease in BP and increase iin HR d/t small histamine release |
|
|
Term
|
Definition
| medium duration of action; metabolized in liver and excreted by kidney; minimal CV or histamine releasing affects |
|
|
Term
|
Definition
| medium duration of action; metabolized in liver and excreted by kidney; minimal CV or histamine releasing affects |
|
|
Term
|
Definition
| long duration of action; slight increase in HR and BP d/t slight histamine release |
|
|
Term
|
Definition
| metabolized by pseudocholinesterase so ultra-short duration of action (genetic polymorphisms) |
|
|
Term
| lysergic acid diethylamide |
|
Definition
|
|
Term
|
Definition
| 5-HT1D receptor is on cerebral blood vessels; not prevention of headaches; SE - nausea, vomiting, angina, dizziness, flushing |
|
|
Term
|
Definition
| females only; not safe for males |
|
|
Term
|
Definition
| SE - sexual dysfunction, nausea |
|
|
Term
|
Definition
| SE - HTN crisis b/c also blocks NE metabolism |
|
|
Term
|
Definition
|
|
Term
|
Definition
| only as a last resort to non-responders to other Tx; can produce severe GI adverse affects |
|
|
